Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...

Viking Therapeutics ( VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Most Tiger-related funds lost money in February. However, they not only remained in the black for the year but continued to ...

Aaron Rodgers, despite challenges with the Jets, could potentially join the Minnesota Vikings, following a path similar to Brett Favre. Favre supports this move, highlighting the Vikings' strong ...

The Minnesota Vikings are set to sign two-time Pro Bowl defensive tackle Javon Hargrave following his release from the San Francisco 49ers. Hargrave, who previously played for the Pittsburgh ...

Because so much happens, and so quickly, it's always important to take stock of what went down ... Importantly, all three deals continued the Vikings' fortification of the trenches: They are ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing contract, removing an overhang that has weighed on the stock for ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics (NASDAQ ...

These two factors combined probably explain why Viking and Roche stocks are up today and Novo Nordisk stock is down. And now, at last, the question of the hour: How does this recent news affect ...

Viking’s long booking window supports the view of its revenue and EBITDA trajectory despite the risk of a slowing economy. Preliminary bookings for 2026 are reportedly ahead of 2025. However, demand ...

On Tuesday, H.C. Wainwright reaffirmed its Buy rating on Viking Therapeutics (NASDAQ:VKTX), with a steady price target of $102.00. Currently trading at $27.96, the stock has significant upside ...